- Location
Sanofi
"-
Multi Packaging Solutions Launches Chattem's Xyzal Allergy 24HR to OTC Market
Apr 5, 2017Multi Packaging Solutions (MPS), a global leader in value-added print and packaging solutions for the healthcare, branded consumer and multi-media markets, has brought agility to the consumer launch of Chattem’s Xyzal Allergy 24HR, ...
Tags: Multi Packaging, OTC Market
-
An Economic Option and Preferred by The Healthcare or Pharmaceutical Industry
Jan 14, 2015Reusable passive packaging is an economic option and is preferred by the healthcare or pharmaceutical industry, according to a survey conducted by global provider of temperature assurance packaging Sonoco ThermoSafe. The 2014 survey was ...
Tags: package efficiency, ownership costs, pricing, Agriculture
-
89% of Customers Believe Strategic Partnership to Be The Most Important Attribute
Nov 26, 2014Over half (53%) of life sciences and healthcare manufacturers prioritise quality assurance over cost in selecting their supply chain partner, and the industry is on the fence (48% vs. 52%) about whether the pharmaceutical industry will soon ...
Tags: Healthcare, Service
-
The Afrezza-Branded Inhaled Insulinwill Be Introduced in The U.S
Aug 15, 2014The Afrezza-branded inhaled insulin from Mannkind (Valencia, CA) will be introduced in the United States in 2015 after Sanofi entered into an agreement with the company, offering up to $925 million for the rights to sell the product ...
-
Putnam Hospital Center Comes to Promoting Healthy Lifestyle Choices
Feb 26, 2014Putnam Hospital Center in Carmel, NY, is leading by example when it comes to promoting healthy lifestyle choices and encouraging workplace wellness. The CEO Roundtable on Cancer has accredited Putnam Hospital Center with the CEO Cancer Gold ...
Tags: Cancer, healthy lifestyle, workplace wellness, organization
-
Latham & Watkins Is Working with Lawyers and Staff to Promote Healthy Lifestyle Choices
Jan 15, 2014Latham & Watkins, a leading global law firm, is working with its lawyers and staff to promote healthy lifestyle choices and encourage workplace wellness. The CEO Roundtable on CancerTM has accredited Latham & Watkins with the CEO Cancer ...
-
Genzyme Has Received a Complete Response Letter From The U.S
Jan 2, 2014Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its supplemental Biologics License Application seeking approval of ...
Tags: Genzyme, Biologics License Application, Lemtrada, multiple sclerosis
-
The French Maker of a Drug Used to Treat Multiple Sclerosis Is "Extremely Disappointed"
Dec 30, 2013The French maker of a drug used to treat multiple sclerosis is "extremely disappointed" it was rejected for U.S. sale, a corporate official said. David Meeker, president of Sanofi's Genzyme subsidiary, maker of the drug Lemtrada, said he ...
-
The Drug Arimidex Reduces Risk of Developing Breast Cancer at High Risk for The Disease
Dec 26, 2013The drug Arimidex reduces the risk of developing breast cancer by more than 50 percent among postmenopausal women at high risk for the disease, according to a new study. The finding, scheduled for presentation Thursday at the San Antonio ...
Tags: Arimidex, breast cancer, postmenopausal women, women health, anastrozole
-
Genzyme Has Obtained an Approval From Health Canada for Its Lemtrada
Dec 17, 2013Genzyme, a Sanofi company, has obtained an approval from Health Canada for its Lemtrada (alemtuzumab) for the treatment of relapsing remitting multiple sclerosis (RRMS). Health Canada has approved Lemtrada for the management of adult ...
-
2014 Will Be a Turnaround Year in That Regard
Dec 17, 2013Hopefully as you are reading this, you are enjoying the holiday season and getting ready for 2014. It's been a chaotic, uneven 2013, and my wish is to see it over with as soon as possible and make a fresh start. Not all of 2013 has been ...
-
Sanofi Has Released Results of a 24-Week Phase Iiib Clinical Trial
Dec 9, 2013Sanofi has released results of a 24-week Phase IIIb clinical trial showing that Lyxumia (lixisenatide) met the primary endpoint of non-inferiority in blood sugar lowering (HbA1c) when administered to patients either before breakfast or the ...
Tags: Diabetes Drug, Medicine
-
Nichia & Everlight Continue to Scrap Over Intellectual Property with Former Taking Action
Dec 5, 2013Nichia and Everlight continue to scrap over intellectual property with the former taking new action, while Cree and Osram make executive appointments and The Connected Lighting Alliance will study commercial indoor SSL. Nichia has ...
-
Sanofi S.A. Has Been Appointed to Its Board of Directors
Dec 4, 2013LED chip, lamp and lighting fixture maker Cree Inc of Durham, NC, USA says that Anne Whitaker, president, North American Pharmaceuticals, of Sanofi S.A., has been appointed to its board of directors. “Anne has proven herself to be a ...
Tags: electrical, LED
-
US-Based Company Unilife Has Signed a 15-Year Global Supply Contract with Hikma
Nov 25, 2013US-based medical device company Unilife has signed a 15-year global supply contract with Hikma Pharmaceuticals for the use of Unifill prefilled syringes with a range of generic injectable drugs. Unilife will supply customized prefillable ...
